Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, presented a poster detailing RE104 Phase 1 data at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona.